Interestingly, PLA2G7 silencing was recently shown to reduce xenograft growth of colon cells expressing mutant p53 and activated Ras [31], indicating that in addition to prostate cancers, PLA2G7 may have potential as a drug target in other cancer types as well. This evidence concerns the gene PLA2G7 and prostate carcinoma.